Advanced Biomed (NASDAQ:ADVB) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Advanced Biomed (NASDAQ:ADVB) to a hold rating in a research note released on Saturday.

Separately, Weiss Ratings raised Advanced Biomed from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 23rd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Advanced Biomed presently has an average rating of “Sell”.

Advanced Biomed Stock Performance

Shares of NASDAQ:ADVB opened at $8.14 on Friday. The company has a market capitalization of $13.43 million, a PE ratio of 1.69 and a beta of -0.39. The stock has a fifty day moving average of $7.24 and a 200-day moving average of $5.67. Advanced Biomed has a one year low of $3.61 and a one year high of $24.23.

Institutional Trading of Advanced Biomed

A hedge fund recently bought a new position in Advanced Biomed stock. GSA Capital Partners LLP purchased a new stake in shares of Advanced Biomed Inc. (NASDAQ:ADVB) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 193,323 shares of the company’s stock, valued at approximately $599,000. GSA Capital Partners LLP owned approximately 11.70% of Advanced Biomed at the end of the most recent quarter.

Advanced Biomed Company Profile

Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.